ClinicalTrials.Veeva

Menu

The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion

A

Assiut University

Status and phase

Not yet enrolling
Early Phase 1

Conditions

Malignant Pleural Effusions (Mpe)

Treatments

Procedure: Intercostal chest tube
Combination Product: Pleurodesis

Study type

Interventional

Funder types

Other

Identifiers

NCT06742099
ICT Malignant Pleural effusion

Details and patient eligibility

About

Approximately half of all patients with metastatic cancer develop a malignant pleural effusion which is likely to lead to a significant reduction in quality of life secondary to symptoms such as dyspnoea and cough. The aim of pleurodesis in these patients is to prevent re-accumulation of the effusion and thereby of symptoms,and avoid the need for repeated hospitalization for thoracocentesis. Numerous clinical studies have been performed to try to determine the optimal pleurodesis strategy, and synthesis of the available evidence should facilitate this. The treatment of MPE is aimed at palliating symptoms since no intervention has been shown to improve survival in this population and since survival is generally limited in cancers that have spread to the pleural space. In this palliative setting, only patients symptomatic from their MPE should be submitted to further intervention. As well, further interventions in symptomatic patients should be limited to those patients who have experienced symptomatic improvement following initial therapeutic thoracentesis. The two main treatment approaches to MPE are to obliterate the pleural space via a pleurodesis procedure or to chronically drain the pleural cavity with Intercostal tube. The aims of this review were to ascertain the optimal procedure in cases of malignant pleural effusion in terms of patients' quality of life post procedure, recurrence of effusion.

Enrollment

20 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All patients presented with malignant pleural effusion to Assiut University Hospital regardless of sex and age

Exclusion criteria

  • All patients presented with pleural effusion other than malignant pleural effusion, including patients with debilitating diseases and terminal patients.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 2 patient groups

Malignant Pleural effusion with pleurodesis
Active Comparator group
Description:
these are patients who have malignant pleural effusion and will have talc injected into the pleural cavity to induce pleurodesis
Treatment:
Combination Product: Pleurodesis
Procedure: Intercostal chest tube
Malignant Pleural effusion with only chest tube for drainage
Active Comparator group
Description:
these are patients who have malignant pleural effusion but will only have intercostal chest tube inserted for drainage
Treatment:
Procedure: Intercostal chest tube

Trial contacts and locations

1

Loading...

Central trial contact

Hussein E Mohamed, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems